Early mucosal healing with exclusive enteral nutrition is associated with improved outcomes in newly diagnosed children with Luminal Crohn's disease

Journal of Crohn's and Colitis

Volumn 10, Issue 10, 2016, Pages 1159-1164

  Grover, Z ^a,b   Burgess, C ^c   Muir, R ^d   Reilly, C ^d   Lewindon, P J ^d,e  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b Queensland Children's Medical Research Institute   (Australia)

^c LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^d WESLEY HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

EEN; Mucosal healing; Simple endoscopic score for CD

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHILD; COHORT ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; DISEASE SEVERITY; EARLY INTERVENTION; ENDOSCOPY; ENTERIC FEEDING; EXCLUSIVE ENTERAL NUTRITION; FEMALE; FOLLOW UP; HEALING; HUMAN; INTESTINE RESECTION; LONGITUDINAL STUDY; LUMINAL CROHN DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSAL HEALING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SCHOOL CHILD; SIMPLE ENDOSCOPIC SCORE FOR CROHN DISEASE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; DIAGNOSTIC IMAGING; INTESTINE MUCOSA; KAPLAN MEIER METHOD; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; WOUND HEALING;

6-MERCAPTOPURINE; AZATHIOPRINE; CHILD; COMBINED MODALITY THERAPY; CROHN DISEASE; ENTERAL NUTRITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WOUND HEALING;

EID: 85019127352     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw075     Document Type: Article

References (19)

1. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7
2. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's djouisease. Gastroenterology 2010;138:463-8
3. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301
4. Shah C, Colombel F, Sands B, et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 2016;43:317-33
5. Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 2013;48:543-51
6. Cohen SA, Gold BD, Oliva S, et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2014;59:516-21
7. Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J Gastroenterol 2014;49:638-45
8. Nuti F, Civitelli F, Bloise S, et al. Prospective evaluation of the achievement of mucosal healing with anti-TNF-a therapy in a paediatric Crohn's disease cohort. J Crohns Colitis 2016;10:5-12
9. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47
10. Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416-21
11. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-12
12. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SESCD. Gastrointest Endosc 2004;60:505-12
13. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9
14. Rutgeerts PJ, Reinisch W, Thakkar R, et al. Early mucosal healing status predicts long-term clinical benefits for adalimumab-treated patients with moderate to severe Crohn's disease. Gastroenterology 2010;138 Suppl 1:S-85
15. Berni Canani R, Terrin G, Borrelli O, et al. Short-and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis 2006;38:381-7
16. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn's disease: A randomized controlled trial. Gastroenterology 2013;145:758-65
17. Panés J, López-Sanromán A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145:766-74
18. Siegel CA, Siegel LS, Hyams JS, et al. A real time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2011;17:30-8
19. Haberman Y, Tickle TL, Dexheimer PJ, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest 2014;124(8):3617-33